GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Shares Outstanding (EOP)

Roquefort Therapeutics (LSE:ROQ) Shares Outstanding (EOP) : 129.15 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Roquefort Therapeutics's shares outstanding for the quarter that ended in Jun. 2024 was 129.15 Mil.

Roquefort Therapeutics's quarterly shares outstanding stayed the same from Dec. 2023 (129.15 Mil) to Jun. 2024 (129.15 Mil).

Roquefort Therapeutics's annual shares outstanding stayed the same from Dec. 2022 (129.15 Mil) to Dec. 2023 (129.15 Mil).


Roquefort Therapeutics Shares Outstanding (EOP) Historical Data

The historical data trend for Roquefort Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Shares Outstanding (EOP) Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Shares Outstanding (EOP)
71.90 129.15 129.15

Roquefort Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Shares Outstanding (EOP) Get a 7-Day Free Trial 71.90 129.15 129.15 129.15 129.15

Competitive Comparison of Roquefort Therapeutics's Shares Outstanding (EOP)

For the Biotechnology subindustry, Roquefort Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roquefort Therapeutics's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roquefort Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Roquefort Therapeutics's Shares Outstanding (EOP) falls into.


;
;

Roquefort Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Roquefort Therapeutics  (LSE:ROQ) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Roquefort Therapeutics Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Roquefort Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines

No Headlines